Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Li XuanYu WangFen HuangErlie JiangLan DengBingyi WuZhiping FanXinquan LiangNa XuJieyu YeRen LinChangxin YinYuanyuan ZhangJing SunMingzhe HanXiao-Jun HuangQi-Fa LiuPublished in: Cancer (2018)
Sorafenib before transplantation, sorafenib maintenance after transplantation, and their combined application all could improve the outcomes for patients with FLT3-ITD AML. Further study is needed to determine whether the use of sorafenib both before and after transplantation might be ideal. Cancer 2018;124:1954-63. © 2018 American Cancer Society.